LI
ALNY icon

LRI Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History

LRI Investments’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.8K Sell
69
-4
-5% -$1.21K ﹤0.01% 751
2026
Q1 		$24K Sell
73
-119
-62% -$40.5K ﹤0.01% 652
2025
Q4 		$76.2K Buy
192
+2
+1% +$885 0.01% 472
2025
Q3 		$86.5K Buy
190
+142
+296% +$57.8K 0.01% 449
2025
Q2 		$15.7K Buy
+48
New +$13.3K ﹤0.01% 751
2024
Q3 		– Sell
-8
Closed -$1.86K – 1144
2024
Q2 		$1.86K Buy
+8
New +$1.26K ﹤0.01% 1061

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LRI Investments's ALNY Position: Q2 2026 in Review

LRI Investments reduced its Alnylam Pharmaceuticals (ALNY) stake by 5.5% in Q2 2026, selling an estimated $1.21K and leaving 69 shares worth $20.8K. The position accounts for ﹤0.01% of the portfolio, ranked #751.

LRI Investments first reported a position in ALNY in Q2 2024 and has held it in 6 quarters since. The position peaked at $86.5K in Q3 2025. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • LRI Investments held 69 shares of Alnylam Pharmaceuticals worth $20.8K as of Q2 2026.
  • LRI Investments sold 4 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.21K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of LRI Investments's portfolio in Q2 2026, its #751 holding.
  • LRI Investments first reported a position in Alnylam Pharmaceuticals in Q2 2024 and has held it in 6 quarters since.
  • LRI Investments's Alnylam Pharmaceuticals position peaked at $86.5K in Q3 2025.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on LRI Investments's 13F filing for Q2 2026, filed 14 Jul 2026.